| |
January 9-10, 2024 | San Francisco, CA
January 16-18, 2024 | Virtual Don't miss this chance to position your company as an industry leader. Join over 500 senior pharma and biotech executives at this can't miss event! - Thought Leadership
- Branding - Networking
- Exhibit & Meeting Space Register today and Save $450! 
|
|
Today’s Big NewsNov 20, 2023 |
| By Nick Paul Taylor Bayer’s plans to turn asundexian into a $5.5 billion a year medicine have taken a hit. The factor XIa inhibitor had “inferior efficacy” to Bristol Myers Squibb and Pfizer’s Eliquis in a phase 3 trial, prompting Bayer to stop the study early while continuing to advance the asset in another indication. |
|
|
|
By Gabrielle Masson An FDA advisory committee has voted against approving Merck & Co.’s gefapixant, a P2X3 receptor antagonist medicine designed to treat adults with chronic cough. |
By Gabrielle Masson Obesity and diabetes-focused Carmot Therapeutics has unveiled plans to go public, braving icy IPO waters that have remained largely frozen over for biotech for more than a year. |
Sponsored by Adaptive Biotechnologies Dr. Sharon Benzeno, Chief Commercial Officer of Immune Medicine at Adaptive Biotechnologies, shines a spotlight on the key immune-driven medicine advancements that show immense promise in transforming diagnoses, treatments, and patient outcomes. |
By Max Bayer Agios' second-in-command PK activator has passed a mid-stage checkpoint, lessening the need for transfusions in select anemia patients and teeing up the second part of a phase 2 study for the middle of next year. |
Sponsored by Cerba Research There were 250 decentralised clinical trials (DCTs) worldwide in 2012. By 2021, there were 1,291. Dan Tanner, chief commercial officer at Cerba Research, explains how the firm is helping to create a new paradigm in clinical trials. |
By Angus Liu A new collaboration between Fosun Pharma’s U.S. branch and consulting firm Treehill Partners will provide additional resources to help companies survive the biotech winter. |
By Nick Paul Taylor Oxurion’s vision was just a mirage. The last program standing in what was once a three-front attack on eye diseases failed Monday, prompting the Belgian biotech to start preparing to file for bankruptcy. |
By Helen Floersh Gene therapy has the potential to dramatically benefit patients with genetic blood disorders but a small study on participants in a clinical trial for sickle cell disease suggests that a key process carried out prior to giving the treatment might cause mutations that make blood stem cells more likely to turn cancerous. |
By James Waldron AstraZeneca has launched a new company to allow CROs and fellow Big Pharmas to pay to access its tried-and-tested digital solutions for running clinical trials. |
By Angus Liu After blasting the U.K.’s drug pricing policy, the pharma industry has secured an improved government spending deal. The agreement will double the annual growth rate for prescription meds over the coming years. |
By Andrea Park For the fourth time already this month, the FDA has issued a notice formally bestowing a Class I label—denoting a heightened risk of serious injury or death—upon a recall of yet another drug delivery device. |
By Fraiser Kansteiner Bayer is recalling one lot of Vitrakvi oral solution in the U.S. after routine stability testing discovered the presence of microbial contamination identified as Penicillium brevicompactum. |
By Ben Adams Sanofi's Icy Hot pain patch and the Shaquille O'Neal Foundation have shared a 20-year history of collaboration. During this time, the duo has worked together to refurbish courts in Las Vegas, Miami and Newark, New Jersey. |
By Heather Landi It marks Aya Healthcare's third M&A deal in five months as the company works to build up its artificial intelligence capabilities for staffing, hiring and retention. |
Fierce podcasts Don’t miss an episode |
| This episode of "The Top Line" is dedicated to Alzheimer’s disease, spotlighting the latest treatments and what lies ahead. Fierce Pharma's Fraiser Kansteiner discusses Leqembi's full approval with Eisai's Alexander Scott. Annalee Armstrong from Fierce Biotech interviews Alzheimer's expert Howard Fillit, M.D., exploring groundbreaking research. Fierce Pharma’s Eric Sagonowsky speaks with Reisa Sperling, M.D., about Leqembi's potential in preventing Alzheimer’s progression before symptoms emerge. |
|
|---|
|
|
|
Tuesday, November 28, 2023 | 11am ET / 8am PT Elevate your biopharmaceutical game! Join our webinar to explore game-changing solutions. Uncover the power of Recombumin® rHA – the consistent, animal-free alternative revolutionizing manufacturing. Don't miss this chance to stay ahead in the advanced therapy landscape. 
|
|
Whitepaper Accelerate drug discovery with high-performance computing (HPC) powered by the cloud Sponsored By: AWS, NVIDIA, and Rescale |
Whitepaper As a leader of technology transfer activities in the industry, Lonza understands the challenges associated with this critical step. Download this White Paper today to learn more. Sponsored by: Lonza |
eBook Emulate in vivo biology with next-generation in vitro technology. Sponsored by: Emulate |
Whitepaper A critical area to consider in selecting a CDMO is their ability to successfully complete technology transfers, which involves an intricate set of activities and disciplines that, if done incorrectly, could result in delays and failures that impact the overall success of your end product. Recognizing what it takes to complete this process effectively and efficiently is crucial to selecting the best partner for your project and product needs. This white paper delivers an analysis of critical success factors for effective technology transfer. Sponsored by: Lonza |
Whitepaper Learn how to develop a high-performing supply chain for cGMP chemicals used throughout your bioprocessing workflows. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
Whitepaper Download our whitepaper to learn about plasmid DNA design considerations for cell and gene therapy applications. Sponsored by: Aldevron, a GMP manufacturing CDMO of DNA, RNA, and Proteins |
Whitepaper This paper explores AI’s potential impact on healthcare and on Medical Affairs (MA) more specifically. It also outlines what MA teams can do now to proactively leverage AI to improve service to their stakeholders. Presented by Blue Matter, strategic consultants in the life sciences |
| Edison Ballroom, New York City |
|
|
| |
|
